白血病细胞端粒酶活性的研究

目的：研究白血病细胞端粒酶活性表达及其意义。方法：采用PCR-ELISA半定量方法测定端粒酶活性。结果：68.6％(59／86)急性白血病(AL)患者和80％(12／15)慢性粒细胞白血病急性变(CML-BP)患者表达高端粒酶活性；而慢性粒细胞白血病慢性期(CML-CP)患者，无一例表达高端粒酶活性。急性淋巴细胞白血病患者端粒酶活性高于急性髓性白血病患者，CML-BP端粒酶活性高于CML-CP，而CML-CP端粒酶活性则低于正常对照组。AL端粒酶活性水平与患者的性别、年龄无关，也与治疗后缓解率无关。结论：激活或上调端粒酶活性在大多数AL发生和慢性粒细胞白血病急性变过程中起着重要作用；端粒酶活性测定可鉴别CML-BP与CML-CP；端粒酶可能是一潜在的治疗白血病的新靶点。

Study on the Expression of Telomerase Activity in Leukemia Cells

Objective:To study on the expression and significance of telomerase activity in leukemia cells.Methods:Telomerase activity was detected by telomeric repeat amplification protocol(TRAP) enzyme linked immunosorbent assay(ELISA).Results:1.Compared to normal control group, the elevated telomerase activity of acute leukemia(AL), chronic myelogenous leukemia blastic phase(CML BP) and chronic myelogenous leukemia chronic phase (CML CP) was 68.6 %(59/86),80 %(12/15) and 0(0/22) respectively. 2. The levels of telomerase activity in acute myeloid leukemia(AML) were higher than in acute lymphocytic leukemia and the levels of telomerase activity of CML BP were higher than in CML CP. 3. The level of telomerase activity in AL was not related to age or sex of the patient and the rate of complete remission(CR).Conclusion:The activation or up regulation of telomerase might play an important role in the genesis of AL and blast crisis of CML.Detection of telomerase activity could serve as a marker of differentiation between CML BP and CML CP.Telomerase may be a potentially new target of antileukemia.